Keros Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Keros Therapeutics

07/08/2023 13:43

* Keros Therapeutics Inc  KROS.OQ  reported a quarterly
adjusted
loss of $1.27​​ per share for the quarter ended in June. The
mean expectation of nine analysts for the quarter was for a loss
of $1.34 per share.
    * Reported revenue was zero​; analysts expected $162.50
thousand. 
    * Keros Therapeutics Inc's reported EPS for the quarter was
a loss
of $1.27​.
    * The mean earnings estimate of analysts had fallen by
about 3.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Keros Therapeutics Inc shares had risen by 2.4% this
quarter and
lost 14.3% so far this year.
    * The company reported a quarterly loss of $37.51 million.
    * Wall Street's median 12-month price target for Keros
Therapeutics Inc is $93.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 7 at 12:43 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -1.34          -1.27          Beat
 Mar. 31 2023      -1.12          -1.26          Missed
 Dec. 31 2022      -1.10          -1.09          Beat
 Sep. 30 2022      -1.23          -0.92          Beat